Compare Quest Diagnostics Inc (DGX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vale SA — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Vale SA trades at $14.69 (market cap $60.78B). The key difference: Vale SA is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Vale SA pays the higher dividend (8.63%). Which is the better fit depends on your goals.
| DGX | VALE | |
|---|---|---|
Market Cap | $22.80B | $60.78B |
Sector | Health | Basic Materials |
52-Week High | $216.02 | $17.82 |
52-Week Low | $166.42 | $9.53 |
Enterprise Value | $28.82B | $77.70B |
Dividend Yield | 1.67% | 8.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VALE trades at $14.18, down 1.94% for the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $38.40B in 2025 with a net income margin of 7.21%, while recent news highlights a $2.6B decarbonization investment and governance developments. Cash flow remains positive, with operating cash flow at $8.80B in 2025.
The outlook is cautious; while analyst consensus is a Buy with a $17.50 price target, fundamental pressures from declining profit margins and a high debt-to-asset ratio of 24.66% pose risks. Upside depends on commodity price stability and execution of strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
